Prothrombin complex concentrate for the management of severe traumatic bleeding in a patient anticoagulated with apixaban

Journal of Clinical Pharmacy and Therapeutics

Volumn 41, Issue 1, 2016, Pages 92-93

  Durie, R ^a,b   Kohute, M ^a,b   Fernandez, C ^a   Knight, M ^a  

^a JERSEY SHORE UNIVERSITY MEDICAL CENTER   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

anticoagulants; blood coagulation factors; hemorrhage; hemostasis

Indexed keywords

APIXABAN; PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; PROTHROMBIN COMPLEX CONCENTRATES; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ABDOMINAL BLUNT TRAUMA; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CASE REPORT; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE CONCENTRATE; GASTROINTESTINAL REFLUX; HEAD INJURY; HEMODIALYSIS; HEMODYNAMIC STRESS; HUMAN; HYPERTENSION; INJURY SEVERITY; INTERNATIONAL NORMALIZED RATIO; LACTIC ACIDOSIS; LAPAROSCOPIC SURGERY; LIVER INJURY; MALE; MEDICAL HISTORY; METABOLIC ACIDOSIS; MIDDLE AGED; PELVIS FRACTURE; PERIPHERAL VASCULAR DISEASE; RIB FRACTURE; SEVERE TRAUMATIC BLEEDING; SPINE FRACTURE; SPLEEN INJURY; SPLENECTOMY; TRAFFIC ACCIDENT; VACUUM ASSISTED CLOSURE; CHEMICALLY INDUCED; HEMORRHAGE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTICOAGULANTS; BLOOD COAGULATION FACTORS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PYRAZOLES; PYRIDONES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84956592155     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12339     Document Type: Article

References (11)

1. Desai NR, Krumme AA, Schneeweiss S, et al,. Patterns of initiation of oral anticoagulation patients with atrial fibrillation-quality and cost implications. Am J Med, 2014; 127: 1075-1082.
2. Siegal DM, Cuker A,. Reversal of novel oral anticoagulants in patients with major bleeding. J Thromb Thrombolysis, 2013; 35: 391-398.
3. Granger CB, Alexander JH, McMurray JJV, et al,. Apixaban versus warfarin in patients with atrial fibrillation. N Eng J Med, 2011; 365: 981-992.
4. Agnelli G, Buller H, Cohen A, et al,. Oral apixaban for the treatment of acute venous thromboembolism. N Eng J Med, 2013; 369: 799-808.
5. ® P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost, 2008; 6: 622-631.
6. Ebright J, Mousa SA,. Oral anticoagulants and status of antidotes for the reversal of bleeding risk. Clin Appl Thromb Hemost, 2014; 2: 105-114.
7. Sarode R, Milling TJ, Refaai MA, et al,. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on Vitamin K antagonists presenting with major bleeding. Circulation, 2013; 128: 1234-1243.
8. Holbrook A, Schulman S, Witt DM, et al,. Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Circulation, 2012; 141: e152S-e184S.
9. Baumann Kreuziger LM, Keenan JC, Morton CT, Dries DJ, Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates. Biomed Res Int, 2014. doi: 10.1155/2014/583794.
10. Douxfils J, Chatelain C, Chatelain B, Dogne JM, Mullier F,. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. J Thromb Haemost, 2013; 110: 283-294.
11. ELIQUIS (apixaban) [package insert]. Princeton, NJ; Bristol-Myers Squibb. Revised March. 2014.